Overview

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Status:
Recruiting
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of venetoclax combined with CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed acute myeloid leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Chinese PLA General Hospital
Collaborators:
Air Force Military Medical University, China
First Hospital of China Medical University
People's Liberation Army (PLA) Strategic Support Force Characteristic Medical Center
The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army
The 960th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army
The General Hospital of Northern Theater Command
The General Hospital of Western Theater Command
Yantai Yuhuangding Hospital
Treatments:
Aclacinomycins
Azacitidine
Cytarabine
Lenograstim
Venetoclax